← Back to Search

Hallucinogen

Psilocybin 300 mcg/kg for Obsessive-Compulsive Disorder (PSILOCD Trial)

Phase 1
Waitlist Available
Led By Francisco A. Moreno, MD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have moderate to severe OCD (DSM-5) after diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID-R).
Failed at least one adequate attempted routine care treatment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 0, and 24 hours after blinded medication ingestion
Awards & highlights

PSILOCD Trial Summary

This trial will study whether psilocybin can help treat OCD and if it is safe to use. It will also look at how the drug works.

Eligible Conditions
  • Obsessive-Compulsive Disorder

PSILOCD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PSILOCD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 0, and 24 hours after blinded medication ingestion
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 0, and 24 hours after blinded medication ingestion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment-phase effects on Obsessive-Compulsive symptom severity
Secondary outcome measures
Acute Incidence of Treatment Emergent Adverse Events
Changes in functional connectivity: 1) between the Caudate Nucleus (CN) and Orbital Frontal Cortex (OFC); 2) within the default mode network (DMN).
Changes in the magnitude of Error Related Negativity (an electroencephalographic biomarker of OCD) assessed by Error-related negativity (voltage) and mid-frontal theta power (time-frequency approach)
+4 more

PSILOCD Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: High-dose PsilocybinExperimental Treatment1 Intervention
Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
Group II: High- or Low-dose PsilocybinExperimental Treatment2 Interventions
Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
Group III: High-dose Psilocybin or LorazepamPlacebo Group2 Interventions
Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psilocybin 300 mcg/kg
2019
Completed Phase 1
~20
Psilocybin 100 mcg/kg
2019
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
511 Previous Clinical Trials
148,273 Total Patients Enrolled
3 Trials studying Obsessive-Compulsive Disorder
192 Patients Enrolled for Obsessive-Compulsive Disorder
Francisco A. Moreno, MDPrincipal InvestigatorProfessor of Psychiatry and Associate Vice President, Diversity and Inclusion

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
Arizona
Other
California
How old are they?
65+
18 - 65
What site did they apply to?
University of Arizona
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Average response time
  • < 2 Days
Most responsive sites:
  1. University of Arizona: < 48 hours
Typically responds via
Email
~2 spots leftby Mar 2025